Steris Buys Synergy Health for $1.9B, Tax Inversion Deals Continue

U.S. medical technology company Steris said it will buy British sterilization services provider Synergy Health for about $1.9 billion in cash and stock, moving its headquarters to the U.K. Andrew Bulkeley, correspondent for The Deal, reveals how Steris is sidestepping the Treasury Department's recent moves to curb tax inversion deals on behalf of U.S. companies. Bulkeley says the chief executives of Steris and Synergy Health don't seem to believe they'll be affected by the Treasury's new rules and perhaps the Treasury needs to strengthen them in order to have any real effect. With this in mind, Bulkeley says he expects U.S. companies to continue to do tax inversion deals despite the government's crusade against them.